Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H12ClNO2 |
Molecular Weight | 213.661 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1
InChI
InChIKey=KPYSYYIEGFHWSV-QMMMGPOBSA-N
InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1
Arbaclofen (STX209, R-baclofen), a selective agonist of GABA-B receptors, has been investigated in clinical trials for the treatment of autism spectrum disorder ASD, phase II and for the treatment of patients with fragile X syndrome in phase III. As a result, the drug did not meet the primary outcome of improved social avoidance in FXS in either study. In spite of positive results in some children with ASD, further study will be needed to replicate and extend these initial findings. Arbaclofen has also been investigated in phase III clinical trials as a treatment for spasticity due to multiple sclerosis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111463 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22993295 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28616094
5 mg BID to 15 mg TID
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
||
|
FDA ORPHAN DRUG |
271808
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/11/858
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m2200
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB08891
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
XX-44
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
DTXSID90219366
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
69308-37-8
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL301742
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
9360
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
100000177226
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
44602
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
NYU6UTW25B
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
C90890
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)